Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12611000701921
Ethics application status
Approved
Date submitted
11/06/2011
Date registered
8/07/2011
Date last updated
19/07/2011
Type of registration
Retrospectively registered
Titles & IDs
Public title
Single-Dose versus Long-Term Antibiotic Prophylaxis for Breast Reconstruction with Tissue Expanders
Query!
Scientific title
Infection Rates in Patients Receiving Single-Dose or Long-Term Antibiotic Prophylaxis for Breast Reconstruction with Tissue Expanders
Query!
Secondary ID [1]
262362
0
Nil
Query!
Universal Trial Number (UTN)
Nil
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Surgical Site Infection
268066
0
Query!
Condition category
Condition code
Infection
268211
268211
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Arm 1: Single Perioperative Antibiotic Dose. Patients received 1-2 grams of cefazolin intravenously within 30 minutes prior to surgery, based on the participant’s weight (1 gram for less than 100 kg & 2 grams for greater than 100 kg).
Arm 2: Prolonged Antibiotic Dose. Patients also received 1-2 grams of cefazolin intravenously within 30 minutes prior to surgery, based on the participant’s weight (1 gram for less than 100 kg & 2 grams for greater than 100 kg). After surgery patients received an additional 24 hours of intravenous dosing of cefazolin and then seven days of cephalexin 500 mg by mouth 3-4 times per day as directed.
Query!
Intervention code [1]
266755
0
Prevention
Query!
Intervention code [2]
266756
0
Treatment: Drugs
Query!
Comparator / control treatment
Dose Comparison - Arm 2: Prolonged Antibiotic Dose
Query!
Control group
Dose comparison
Query!
Outcomes
Primary outcome [1]
268948
0
Primary Outcome 1: Superficial Surgical Site Infection as defined by the Centers for Disease Control (CDC)
Query!
Assessment method [1]
268948
0
Query!
Timepoint [1]
268948
0
Timepoint: At 2 and 6 weeks and 3 months post-operation
Query!
Secondary outcome [1]
276672
0
Nil
Query!
Assessment method [1]
276672
0
Query!
Timepoint [1]
276672
0
Nil
Query!
Eligibility
Key inclusion criteria
1. Age greater than or equal to 18
2. Female
3. Patients undergoing mastectomy with immediate breast reconstruction with tissue expanders
4. Patients who sign informed consent
5. Patients who do not meet any of the exclusion criteria
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Age less than or equal to 17
2. Patients with ongoing systemic infection at the time of surgery
3. Patients who are pregnant or planning to become pregnant
4. Patients allergic to cephalosporins
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
From October 2008 to December 2010 all patients presenting to 3 breast surgeons' clinic whose disease necessitated either single or bilateral mastectomy and who elected to have immediate breast reconstruction with tissue expanders were screened for inclusion and exclusion criteria. Once a potential study participant was identified, a member of the research team approached the patient with regard to inclusion in this study during their pre-surgical consultation with the breast surgeon. During the consultation, patients were given an informed consent document, and had the study explained to them. Those patients wishing to participate in the study and meeting inclusion criteria were then stratified to receive either a single dose of antibiotics prior to surgery or seven days of oral antibiotics in addition to the dose given prior to surgery.
Allocation to study treatment was concealed. Members of the study team responsible for determining inclusion eligibility were unaware of which group the subject would be allocated. Individuals enrolling study participants contacted a single study investigator, located off-site, for randomization to a study arm. This investigator was solely responsible for maintaining the randomization list and assigning patients to study groups and was not involved in subject screening or in subject consenting.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A random number table was used to generate random number sequences for each block. Then the numbers were divided into 3 digit numbers and treatment A assigned to the first 5 numbers in the sequence and treatment B assigned to the last 5 numbers in the sequence. Four blocks of random sequences were prepared for each plastic surgeon participating in the study.
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
26/10/2008
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
80
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
3625
0
United States of America
Query!
State/province [1]
3625
0
Query!
Funding & Sponsors
Funding source category [1]
267237
0
Self funded/Unfunded
Query!
Name [1]
267237
0
Query!
Address [1]
267237
0
Query!
Country [1]
267237
0
Query!
Primary sponsor type
University
Query!
Name
The University of Kansas School of Medicine - Wichita
Query!
Address
1010 N. Kansas
Wichita, KS 67214
Query!
Country
United States of America
Query!
Secondary sponsor category [1]
266302
0
None
Query!
Name [1]
266302
0
Query!
Address [1]
266302
0
Query!
Country [1]
266302
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
269228
0
The University of Kansas School of Medicine - Wichita Human Subjects Committee 2
Query!
Ethics committee address [1]
269228
0
The University of Kansas School of Medicine - Wichita Office of Compliance 1010 N. Kansas Wichtia, KS 67214-3199
Query!
Ethics committee country [1]
269228
0
United States of America
Query!
Date submitted for ethics approval [1]
269228
0
03/03/2008
Query!
Approval date [1]
269228
0
13/05/2008
Query!
Ethics approval number [1]
269228
0
220081105
Query!
Ethics committee name [2]
269229
0
Via Christi Regional Medical Center Institutional Review Board
Query!
Ethics committee address [2]
269229
0
Medical Staff Administration Via Christi Regional Medical Center 929 N. Saint Francis Wichita, KS 67214
Query!
Ethics committee country [2]
269229
0
United States of America
Query!
Date submitted for ethics approval [2]
269229
0
29/02/2008
Query!
Approval date [2]
269229
0
27/03/2008
Query!
Ethics approval number [2]
269229
0
Query!
Ethics committee name [3]
269230
0
Wichita Medical Research & Education Foundation Institutional Review Board
Query!
Ethics committee address [3]
269230
0
Wichita Medical Research & Education Foundation 3306 E. Central Wichita, KS 67208
Query!
Ethics committee country [3]
269230
0
United States of America
Query!
Date submitted for ethics approval [3]
269230
0
24/07/2007
Query!
Approval date [3]
269230
0
02/09/2008
Query!
Ethics approval number [3]
269230
0
1/08/0035
Query!
Summary
Brief summary
This small study did not reveal a significant difference between single-dose versus long-term antibiotic prophylaxis, although all infections occurred in patients in the single-dose antibiotic group. Further studies are needed to determine whether the common practice of prolonged antibiotic use after immediate reconstruction with tissue expanders is beneficial.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
32733
0
Query!
Address
32733
0
Query!
Country
32733
0
Query!
Phone
32733
0
Query!
Fax
32733
0
Query!
Email
32733
0
Query!
Contact person for public queries
Name
15980
0
Stephen D. Helmer, Ph.D.
Query!
Address
15980
0
Department of Surgery, Room 3082
The University of Kansas School of Medicine - Wichita
929 N. Saint Francis St.
Wichita, KS 67214
Query!
Country
15980
0
United States of America
Query!
Phone
15980
0
1 316 2685457
Query!
Fax
15980
0
1 316 2917662
Query!
Email
15980
0
[email protected]
Query!
Contact person for scientific queries
Name
6908
0
Stephen D. Helmer, Ph.D.
Query!
Address
6908
0
Department of Surgery, Room 3082
The University of Kansas School of Medicine - Wichita
929 N. Saint Francis St.
Wichita, KS 67214
Query!
Country
6908
0
United States of America
Query!
Phone
6908
0
1 316 2685457
Query!
Fax
6908
0
1 316 2917662
Query!
Email
6908
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF